Literature DB >> 3499007

A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions.

P M Sandset1, U Abildgaard, M Pettersen.   

Abstract

We have previously shown that addition of adsorbed plasma to a mixture of TP and FVII reduces the amount of subsequently added FX that can be activated. We now report that this inhibitory effect of plasma is increased dramatically by first incubating TP and FVII with a minor amount of FX. This results in a progressive loss in the ability of TP-FVIIa to convert subsequently added FX to FXa. An assay system quantitating the inhibitory effect of 1 microliter of heated, citrated plasma is described. Optimal inhibition is obtained when the initial amount of FX added is about 0.00125 U, which is 1/16 of the amount used as reagent to measure remaining TP-FVIIa. FVII and FX must be removed from test plasma prior to assay. The inhibitory activity is reduced more by BaSO4 adsorption than by heating plasma to 56 degrees C for 15 minutes. Gel filtration of plasma separates three distinct fractions with inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499007     DOI: 10.1016/0049-3848(87)90454-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.

Authors:  Florry E van den Boogaard; Cornelis van 't Veer; Joris J T H Roelofs; Joost C M Meijers; Marcus J Schultz; George J Broze; Tom van der Poll
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

2.  Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.

Authors:  P M Sandset; B J Warn-Cramer; L V Rao; S L Maki; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

3.  Identification of a domain in apolipoprotein B-100 that inhibits the procoagulant activity of tissue factor.

Authors:  C Ettelaie; N J James; J M Adam; K P Nicola; B R Wilbourn; K R Bruckdorfer
Journal:  Biochem J       Date:  1998-07-15       Impact factor: 3.857

4.  The effects of continuous venovenous hemofiltration on coagulation activation.

Authors:  Catherine S C Bouman; Anne-Cornélie J M de Pont; Joost C M Meijers; Kamran Bakhtiari; Dorina Roem; Sacha Zeerleder; Gertjan Wolbink; Johanna C Korevaar; Marcel Levi; Evert de Jonge
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

5.  Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia.

Authors:  Florry E van den Boogaard; Jorrit J Hofstra; Cornelis van 't Veer; Marcel M Levi; Joris J T H Roelofs; Tom van der Poll; Marcus J Schultz
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.